DD3 Test

Differential display code 3, also known as DD3, is a promising test for the diagnosis of prostate cancer. It can help determine if a repeat prostate biopsy is indicated so as to help detect prostate cancer.

To do the test, the first amount of urine would be collected after a healthcare practitioner and then it would perform a digital rectal exam (DRE).

The PCA3 test result is a ratio of PCA3 mRNA to PSA mRNA. However, the test does not provide a definitive answer as to whether a man has a cancer or not.

Instead,  the test results together with other data are required to determine the likelihood that a repeat biopsy will be positive.

A PCA3 score that is less than the laboratory’s established cutoff is considered negative and is associated with a decreased likelihood of a positive biopsy.

About 90% of prostate cancers will over-express PCA3, but the PCA3 result cannot be used to diagnose or completely rule out prostate cancer, but it is still the gold standard for diagnosing prostate cancer.

Keywords: DD3, Differential Display Code 3, PCA3, Prostate Cancer Antigen 3

* The contents of this HTQ Site are for informational and communicational purposes only. The information provided by HTQ, HTQ employees, others appearing on the Site at the invitation of HTQ, or other visitors to the Site is NOT a medical advice.The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on the HTQ Site!